Predominantly defective CD8⁺ T cell immunity to SARS-CoV-2 mRNA vaccination in lung transplant recipients.

ABSTRACT:

Background

Although mRNA vaccines have overall efficacy preventing morbidity/mortality from SARS-CoV-2 infection, immunocompromised persons remain at risk. Antibodies mostly prevent early symptomatic infection, but cellular immunity, particularly the virus-specific CD8⁺ T cell response, is protective against disease. Defects in T cell responses to vaccination have not been well characterized in immunocompromised hosts; persons with lung transplantation are particularly vulnerable to vaccine failure with severe illness.

Methods

Comparison groups included persons with lung transplantation and no history of COVID-19 (21 and 19 persons after initial mRNA vaccination and a third booster vaccination respectively), 8 lung transplantation participants recovered from COVID

SUBMITTER: Taus E 

PROVIDER: S-EPMC10248978 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature